PDS BIOTECHNOLOGY CORPORATION - COMMON STOCK

PDS Biotechnology Announces Conference Call and Webcast for Third Quarter 2023 Financial Results

07 Nov 2023 07:00:01 By Nasdaq GlobeNewswire

PDS Biotech Announces Preliminary Biomarker Study Results in Subset of Advanced HPV-Positive Head and Neck Cancer Patients at ESMO

23 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

PDS Biotech Announces Interim Safety and Immune Response Data from Phase 1/2 Clinical Trial Evaluating Novel Antibody Drug Conjugate PDS0301 Combined with Docetaxel to Treat Metastatic Prostate Cancer

11 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

PDS Biotech Announces Interim 24-Month Survival Rate of 74% in Immune Checkpoint Inhibitor Naïve Head and Neck Cancer Patients Treated with PDS0101 in Combination with KEYTRUDA® (pembrolizumab)

03 Oct 2023 06:00:00 By Nasdaq GlobeNewswire

PDS Biotech Announces PDS0101 Combined with Chemoradiotherapy Associated with Rapid Decline in Circulating Tumor DNA (ctDNA/cfDNA)

02 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

PDS Biotech to Present at the LD Micro Main Event XVI

26 Sep 2023 07:00:00 By Nasdaq GlobeNewswire

PDS Biotech Reschedules Key Opinion Leader Roundtable Addressing Current and Future Treatments for Recurrent/Metastatic HPV-Positive HNSCC and the Potential Application of PDS0101

25 Sep 2023 07:00:13 By Nasdaq GlobeNewswire

PDS Biotech to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference

20 Sep 2023 15:05:00 By Nasdaq GlobeNewswire

PDS Biotech Announces PDS0202 Elicits Active Neutralization of Multiple Influenza Strains in Preclinical Studies

20 Sep 2023 07:00:18 By Nasdaq GlobeNewswire

PDS Biotech to Host Key Opinion Leader Roundtable Addressing Current and Future Treatments for Recurrent/Metastatic HPV-Positive HNSCC and the Potential Application of PDS0101 on September 27, 2023

13 Sep 2023 07:00:00 By Nasdaq GlobeNewswire

PDS Biotech to Participate at the H.C. Wainwright 25th Annual Global Investment Conference

06 Sep 2023 15:05:00 By Nasdaq GlobeNewswire

PDS0202 Universal Influenza Preclinical Ferret Data to be Presented in Oral Lecture at 9th ESWI Conference

06 Sep 2023 07:00:00 By Nasdaq GlobeNewswire

PDS Biotech Announces Data from IMMUNOCERV Phase 2 Trial Investigating PDS0101 and Chemoradiotherapy in Cervical Cancer to be Featured in Oral Presentation at the ASTRO 2023 Annual Meeting

16 Aug 2023 07:00:01 By Nasdaq GlobeNewswire

PDS Biotech Reports Second Quarter 2023 Financial Results and Provides Business Update

14 Aug 2023 06:30:00 By Nasdaq GlobeNewswire

PDS Biotech Announces Submission of Phase 3 Protocol to FDA to Initiate VERSATILE-003 Trial

14 Aug 2023 06:00:01 By Nasdaq GlobeNewswire

PDS Biotechnology Announces Conference Call and Webcast for Second Quarter 2023 Financial Results

07 Aug 2023 07:00:01 By Nasdaq GlobeNewswire

PDS Biotech to Present at BTIG Virtual Biotechnology Conference 2023

02 Aug 2023 07:00:02 By Nasdaq GlobeNewswire

PDS Biotech Announces Acceptance of Abstract on Combination of PDS0301 with Docetaxel in Metastatic Prostate Cancer for Oral Presentation by the National Cancer Institute at Cytokines 2023

17 Jul 2023 07:00:01 By Nasdaq GlobeNewswire

PDS Biotech Strengthens Intellectual Property Portfolio Governing A Combination of Versamune® and PDS0301

11 Jul 2023 07:00:01 By Nasdaq GlobeNewswire

PDS Biotechnology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

30 Jun 2023 15:05:00 By Nasdaq GlobeNewswire